Kirchhof P,? Lip G Y,? Van-Gelder I C, et al. Comprehensive risk reduction in patients with atrial fibrillation:? emerging diagnostic and therapeutic options: a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference[J]. Europace,? 2012,? 14(1): 8-27.? [2]Workman A J,? Smith G L,? Rankin A C. Mechanisms of termination and prevention of atrial fibrillation by drug therapy[J]. Pharmacol Ther,? 2011,? 131(2): 221-241.? [3]Munger T M,? Wu L Q,? Shen W K. Atrial fibrillation[J]. J Biomed Res,? 2014,? 28(1): 1-17.? [4]Zhao W,? Zhao D,? Yan R, et al. Cardiac oxidative stress and remodeling following infarction:? role of NADPH oxidase[J]. Cardiovasc Pathol,? 2009,? 18(3): 156-166.? [5]Anilkumar N,? Sirker A,? Shah A M. Redox sensitive signaling pathways in cardiac remodeling,? hypertrophy and failure[J]. Front Biosci (Landmark Ed),? 2009,? 14: 3168- 3187. [6]Tsujimoto I,? Hikoso S,? Yamaguchi O, et al. The antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophy[J]. Hypertension,? 2005,? 45(5):? 921-926.? [7]徐洪,? 杨方,? 袁媛,? 等. 免疫组织化学Image Pro Plus图像半定量分析的参数选择[J]. 解剖学杂志,? 2012,? 35(1): 37-41.? [8]李勇,? 马瑞彦,? 肖颖彬,? 等. 风湿性二尖瓣病变并发心房颤动患者483例临床分析[J]. 第三军医大学学报,? 2011,? 33(10): 1048-1051.? [9]Boos C J,? Anderson R A,? Lip G Y. Is atrial fibrillation an inflammatory disorder?[J]. Eur Heart J,? 2006,? 27(2): 136-149. [10]Anselmi A,? Possati G,? Gaudino M. Postoperative inflammatory reaction and atrial fibrillation:? simple correlation or causation?[J]. Ann Thorac Surg,? 2009,? 88(1): 326-333.? [11]戴天医,? 罗太阳,? 何怡华,? 等. 犬房颤模型心房纤维化对心房重塑和炎症水平的影响[J]. 第三军医大学学报,? 2013,? 35(22): 2409-2414.? [12]Korantzopoulos P,? Kolettis T M,? Galaris D, et al. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation[J]. Int J Cardiol,? 2007,? l15(2): 135-143.? [13]Leftheriotis D I,? Fountoulaki K T,? Flevari P G, et al. The predictive value of inflammatory and oxidative markers following the successful cardiovascular of persistent lone atrial fibrillation[J]. Int J Cardiol,? 2009,? 135(3): 361-369.? [14]Bedard K,? Krause K H. The NOX family of ROS-generating NADPH oxidases:? physiology and pathophysiology[J]. Physiol Rev,? 2007,? 87(1): 245-313.? [15]Brandes R P,? Weissmann N,? Schroder K. NADPH oxidases in cardiovascular disease[J]. Free Radic Biol Med,? 2010, 49(5): 687-706.? [16]Dudley S C Jr,? Hoch N E,? McCann L A, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage:? role of the NADPH and xanthine oxidases[J].Circulation,? 2005,? 112(9): 1266-1273.? [17]Rodino-Janeiro B K,? Paradela-Dobarro B,? Castineiras-Landeira M I, et al. Current status of NADPH oxidase research in cardiovascular pharmacology[J].Vasc Health Risk Manag,? 2013,? 9: 401-428.? [18]Danzig V,? Mikova B,? Kuchynka P, et al. Levels of circulating biomarkers at rest and after exercise in coronary artery disease patients[J]. Physiol Res,? 2010,? 59(3):? 385-392.? [19]Brandes R P,? Weissmann N,? Schroder K. NOX family NADPH oxidases:? Molecular mechanisms of activation[J]. Free Radic Biol Med,? 2014,? 76C: 208-226.
[2]
肖培林,高崇翰,范晋奇,等.RAS阻断剂对实验性高甲状腺素毒性兔心房电生理和离子通道表达的影响[J].第三军医大学学报,2011,33(16):1726. Xiao Peilin,Gao Chonghan,Fan Jinqi,et al.Effect of renin angiotensin system blocker on atrial electrophysiology and ion channel expression in hyperthyroid rabbits[J].J Third Mil Med Univ,2011,33(01):1726.